Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

InnoScience (Suzhou) Technology Holding Co., Ltd.
英諾賽科(蘇州)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2577)

GRANT OF SHARE AWARD UNDER THE 2025 SHARE AWARD PLAN

Reference is made to the circular dated 19 June, 2025 (the "**Circular**") issued by InnoScience (Suzhou) Technology Holding Co., Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") in relation to, among other things, the proposed adoption of the 2025 Share Award Plan (the "**2025 Share Award Plan**" or the "**Plan**"). The 2025 Share Award Plan was approved and duly adopted by the Shareholders at the 2025 First Extraordinary General Meeting held on 9 July, 2025. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular and the 2025 Share Award Plan.

The Board of Directors of the Company (the "**Board**") announces that on 2 November, 2026, pursuant to the 2025 Share Award Plan, the Company granted Share Award involving a total of 3,273,300 H shares of the Company ("**H Shares**") (the "**Grant**") to 154 eligible participants (all being employees of the Group, the "**Grantees**"), subject to acceptance by each of the Grantees.

The 3,273,300 Awarded Shares involved in the Grant will be fully satisfied by existing H Shares previously purchased from the market by the Trustee under the Plan and held in trust. The Grant does not involve any issue of new H Shares or transfer of treasury shares by the Company, and therefore will not lead to any dilution of the shareholdings of the existing Shareholders as a result of the Grant.

Details of the Grant

Date of Grant:	2 November, 2026
Number and category of Grantees:	154 employee participants, including Mr. Wu Lei, the employee representative director and executive director of the Company.
Number of Awarded Shares granted:	A total of 3,273,300 H Shares.

Purchase price of the Awarded Shares:	HK$5.00 per H Share. The purchase price was determined with reference to factors including the market price of the H Shares, the purpose of the Plan, the characteristics and background of the Grantees, and the incentive purpose of the Grant. There is no arrangement for the Company and its subsidiaries to provide financial assistance to the Grantees to assist them in purchasing the Awarded Shares under the Plan.
Closing price of the H Shares on the date of grant:	HK$26.7.
Vesting period and vesting schedule:	Subject to the fulfillment of the vesting conditions set out in the Plan and the Grant Letter, the Awarded Shares shall vest in four tranches: 25% each on the first trading day after the expiry of 12 months, 24 months, 36 months, and 48 months from the Date of Grant, respectively.
Vesting conditions and performance targets:	According to the Plan and the Grant Letter, provided that the employment contract between the Grantee and the Company remains valid and unexpired, and that the Grantee has not been subject to any circumstances stipulated in Article 39 of the Labour Contract Law of the People's Republic of China within the past 12 months, the Trustee shall effect the vesting of the Awarded Shares upon the fulfillment of relevant conditions prescribed in the Plan, which include reaching the applicable vesting date and the receipt of required information and documents by the Trustee within the stipulated time-frame. The Grant is not subject to any performance targets. The Remuneration Committee of the Board (the "**Remuneration Committee**"), having considered the purpose of the Grant, the vesting arrangements, the contributions of the Grantees to the long-term development of the Group, and the incentive and constraint mechanisms set out in the Plan and the Grant Letter, is of the view that it is appropriate and in line with the incentive purpose of the Plan to make the Grant without setting additional performance targets.

Clawback/lapse mechanism:	If (i) the Grantees ceases to be an employee of the Group (except as otherwise provided in the Plan); (ii) the subsidiary by which the Grantees is employed ceases to be a member of the Group; (iii) the Grantees is involved in circumstances such as misconduct, bankruptcy or insolvency as specified in the Plan, or is convicted of any criminal offence involving his/her integrity or honesty; (iv) the Grantees can no longer contribute to the growth and development of any member of the Group due to the termination of his/her relationship with the Group or for other reasons; (v) the Grantees fails to satisfy any applicable vesting conditions; or (vi) other events of full or partial lapse as specified in the Plan occur, the relevant unvested Share Award shall lapse and be cancelled in whole or in part. In the event of any serious misconduct by the Grantees, including fraud, dishonesty, material dereliction of duty, serious damage to the interests of the Group, or unauthorized use or disclosure of confidential information, in addition to the lapse and cancellation of the relevant unvested Share Award, to the extent permitted by the Plan and applicable laws and regulations, the Company, the Board or person(s) authorized by the Board may also take appropriate remedial measures in respect of the relevant Share Award previously vested to the Grantees, including requiring the return of the relevant Awarded Shares.

Reasons for and Benefits of the Grant

The Grant aims to recognize and motivate the Grantees for their past and expected future contributions to the Group, and align the interests of the Grantees with the long-term interests of the Group and the Shareholders through the Share Award. By doing so, the Company can attract, retain and motivate talents who play crucial roles in the continuous development of the Group, enhance employee enthusiasm and loyalty, and further promote the long-term and stable development of the Company. The Remuneration Committee is of the view that the terms of the grant of the Share Award are fair and reasonable, and that the Grant is in line with the purpose of the Plan and in the overall interests of the Company and the Shareholders.

Listing Rules Implications

The Grant will be satisfied by the existing H Shares purchased from the market and held in trust by the Trustee under the Plan, and the Company will not issue new H Shares or transfer treasury shares for the Grant. The Grant has been approved by the Remuneration Committee in accordance with the Plan.

The Grantees of this Grant include Mr. Wu Lei, the employee representative director and executive director of the Company, who has been granted 60,000 Awarded Shares. Prior approval of the independent non-executive directors has been obtained for the grant to Mr. Wu Lei in accordance with the provisions of the Plan and Rule 17.04(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Within the 12-month period up to and including the date of grant, the total number of H Shares involved in all awards granted to Mr. Wu Lei by the Company (excluding any awards which have lapsed in accordance with the terms of the Plan) does not exceed 0.1% of the H Shares in issue (excluding treasury shares) as at the date of grant, and therefore the grant is not subject to the separate approval of the Shareholders.

To the best of the knowledge, information and belief of the directors having made all reasonable enquiries, save as disclosed above, none of the Grantees is: (i) a director, chief executive or substantial Shareholder of the Company, or an associate of any of them; (ii) a participant who has been or will be granted awards exceeding the 1% individual limit stipulated under Rule 17.03D of the Listing Rules; or (iii) a related entity participant or service provider (as defined in the Listing Rules) who has been or will be granted awards exceeding the limit of 0.1% of the total number of issued shares (excluding treasury shares) in any 12-month period. This grant is not subject to Shareholders' approval.

Under Chapter 14A of the Listing Rules, Mr. Wu Lei, the employee representative director and executive director of the Company, is a connected person of the Company. Accordingly, the grant of Awarded Shares to Mr. Wu Lei constitutes a Connected Transaction of the Company under Chapter 14A of the Listing Rules. As the grant of Awarded Shares to Mr. Wu Lei forms part of his remuneration package under his service contract entered into with the Company, and the grant does not involve the issue of any new H Shares or the transfer of treasury shares, the grant is therefore exempt from the reporting, announcement and independent Shareholders' approval requirements pursuant to Rules 14A.73(6) and 14A.95 of the Listing Rules.

Plan Mandate Limit

The Plan Mandate Limit of the Plan shall not exceed 10% of the total number of issued H Shares (excluding treasury shares) as at the Adoption Date, being 49,125,718 H Shares. Prior to the Grant, the Trustee has cumulatively purchased 4,822,100 H Shares from the market in accordance with the terms and conditions of the Plan and holds them in trust for the benefit of the Eligible Participants.

Prior to the Grant, no Awards have been granted under the Plan. After taking into account the Grant, the number of Shares available for future grants under the Plan Mandate Limit of the Plan is 45,852,418 H Shares.

By order of the Board
InnoScience (Suzhou) Technology Holding Co., Ltd.
英諾賽科(蘇州)科技股份有限公司
Dr. Weiwei Luo
Chairperson and Executive Director

PRC, 2 November, 2026

As at the date of this announcement, the Board of the Company comprises Dr. Weiwei Luo, Mr. Jay Hyung Son, Dr. Wu Jingang and Mr. Wu Lei as executive directors; Dr. Wang Can and Ms. Zhang Yanhong as non-executive directors; and Mr. Wong Hin Wing, MH, JP, Dr. Yi Jiming and Dr. Yang, Simon Shi-Ning as independent non-executive directors.